SVNS.LSE Solvonis Therapeutics plc
- Market cap
- GBX 6.47M
- P/E
- -
- P/B
- 1.56x
- ROE
- -119.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is SVNS.LSE undervalued?
Graham numberThe Graham number of Solvonis Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Solvonis Therapeutics plc fundamental analysis
No fundamental analysis for Solvonis Therapeutics plc yet.
Solvonis Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic …
Full company profileSolvonis Therapeutics plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Solvonis Therapeutics plc annual financial statements
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 29.0K | 330K | 219K | 542K | 587K | 0.00 | 0.00 | - |
| Gross Profit | -8.00K | 16.0K | 284K | 55.0K | -51.0K | -134K | 0.00 | - | - |
| Operating Income | -384K | -475K | -466K | -845K | -2.71M | -2.21M | -1.38M | -3.48M | -5.75M |
| EBITDA | -486K | -618K | -352K | -900K | -2.59M | -2.94M | -1.38M | -5.74M | -5.75M |
| Net Income | -494K | -703K | -538K | -954K | -2.71M | -3.12M | -1.59M | -5.74M | -5.75M |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.03 | -0.03 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||
| Total Assets | 3.10M | 2.76M | 2.59M | 3.13M | 4.94M | 2.43M | 3.20M | 7.59M | 6.43M |
| Total Liabilities | 152K | 520K | 890K | 2.32M | 385K | 408K | 119K | 1.39M | 1.62M |
| Shareholders' Equity | 2.95M | 2.24M | 1.70M | 812K | 4.55M | 2.03M | 3.08M | 6.19M | 4.81M |
| Cash & Short-term Investments | 339K | 90.0K | 25.0K | 598K | 1.64M | 155K | 757K | 1.72M | 659K |
| Total Debt | 102K | 405K | 571K | 950K | 22.0K | 34.0K | - | 75.0K | 72.0K |
| Cash Flow | |||||||||
| Operating Cash Flow | -413K | -560K | -192K | -254K | -2.36M | -1.24M | -1.13M | -3.27M | - |
| Capital Expenditure | 516K | 20.0K | 8.00K | 1.00K | 718K | 232K | 4.00K | 0.00 | - |
| Free Cash Flow | -929K | -580K | -200K | -255K | -3.08M | -1.47M | -1.13M | -3.27M | - |
| Ratios | |||||||||
| ROE | -16.8% | -31.4% | -31.6% | -117.5% | -59.4% | -154.0% | -51.6% | -92.7% | -119.5% |
| ROA | -16.0% | -25.5% | -20.7% | -30.5% | -54.8% | -128.2% | -49.6% | -75.7% | -89.4% |
| Net Profit Margin | - | -2,424.1% | -163.0% | -435.6% | -499.1% | -531.5% | - | - | - |
| Debt to Equity | 0.03x | 0.18x | 0.34x | 1.17x | 0.00x | 0.02x | - | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Solvonis Therapeutics plc dividends
Solvonis Therapeutics plc has not paid dividends in the last 8 fiscal years.
Who owns Solvonis Therapeutics plc
- Insiders 26.44%
- Institutions 1.88%
- Public & others 71.69%
- Shares outstanding 6.81B
- Free float 5.11B
Solvonis Therapeutics plc company profile
- Company name
- Solvonis Therapeutics plc
- Ticker
- SVNS.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6
- Fiscal year end
- December
- Address
- Eccleston Yards, London, United Kingdom, SW1W 9NF
- Phone
- 44 77 9543 0246
- Website
- solvonis.com
About Solvonis Therapeutics plc
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
Solvonis Therapeutics plc management
4- Mr. Anthony James TennysonCEO & Executive Director · born 1976
- Mr. Victor BolduevFounder · born 1957
- Mr. Ryan Paul NeatesChief Financial Officer · born 1991
- Dr. David John Nutt DM, FMedSci, FRCP, FRCPsych, FSB, Ph.D.Chief Scientific Advisor